60 Degrees Pharma Announced IRB Approval of Phase IIA Study to Evaluate Tafenoquine for Babesiosis, an Emerging Tick-Borne Disease; Type C Meeting Re-Scheduled by FDA to January 17, 2024

Source :: Plus Company Updates. December 26, 2023
Publication Year :: 2023
Abstract: WASHINGTON: 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (60P or the Company), a pharmaceutical company focused on developing new medicines for infectious diseases, announced today the approval of an Investigational [...]

Subjects :: United States. Food and Drug Administration
Tafenoquine
Clinical trials
Babesiosis -- Care and treatment
General interest
News, opinion and commentary

Tools